Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
Walnut Creek, CA, USA, February 14th, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, will present at the upcoming 2022 BIO CEO & Investor Conference, which will be held in New York City on February 14-17, 2022. Hosted by the Biotechnology Innovation Organization (BIO) for over 20 years, the annual […]
Dr. Volker W. Stieber, MD, Joins Vivacitas’ Neuro-Oncology Advisory Board
Walnut Creek, CA, USA, February 7, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, is proud to present Dr. Volker W. Stieber, MD, as a welcome addition to its distinguished Neuro-Oncology Advisory Board. Dr. Volker W. Stieber, MD Dr. Stieber is board certified in Radiation Oncology. He is a graduate […]
Vivacitas Oncology Strengthens its Neuro-Oncology Board with World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN
Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory Board with top clinicians and researchers in the field with the addition of Dr. Katherine Peters, MD, PhD, FAAN, Associate Professor of Neurosurgery at Duke University School of Medicine. About […]
Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
Vivacitas will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit.